The Tenovus 'Sing for Life' choir

Share :
Published: 28 Dec 2010
Views: 6305
Rating:
Save
Claudia McVie - Tenovus, Cardiff, UK
Claudia McVie talks about the history of Tenovus and the work that the organisation has done to aid the fight against cancer. The early work of Tennovus included funding research on drugs such as tamoxifen, establishing specialist oncology nurses and developing a support line for cancer patients. Tenovus has brought a choir of 78 cancer patients who will be opening the 2010 NCRI meeting. Ms McVie discusses the research, funded by Tenovus and carried out with Cardiff University, to assess how singing can be beneficial to lung cancer patients. Tenovus is also displaying their community bus at the NCRI meeting. The Tenovus bus aims to support cancer patients by going into the community to prevent patients from having to travel long distances for chemotherapy or consultations.

Related Videos

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )
23 Oct 2024

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )
23 Oct 2024

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

Dr Rom Leidner - Providence Cancer Institute, Portland, USA
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )
17 Oct 2024

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )
9 Oct 2024

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Prof Benjamin Besse - Gustave Roussy, Paris, France
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )
1 Oct 2024

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )
1 Oct 2024

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024